A cross-sectional study of prescribing rates for SGLT2 inhibitors and GLP-1 receptor agonists among primary care clinics with and without embedded pharmacists
- 27 March 2026
- journal article
- Published by Elsevier in Journal of the American Pharmacists Association
- Vol. 66 (4) , 103106
Abstract
No abstract availableKeywords
Funding Information
- European Bank for Reconstruction and Development (UM1TR004360)
- Boehringer Ingelheim
- National Center for Advancing Translational Sciences
This publication has 21 references indexed in Scilit:
- Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 DiabetesJAMA Cardiology, 2021
- Trends in Clinical Characteristics and Prescribing Preferences for SGLT2 Inhibitors and GLP-1 Receptor Agonists, 2013–2018Diabetes Care, 2020
- Therapeutic Inertia in Cardiovascular Disease PreventionJACC, 2019
- 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood CholesterolJACC, 2019
- Prescription of Glucagon-Like Peptide-1 Receptor Agonists by CardiologistsJACC, 2019
- Prescriber Patterns of SGLT2i After Expansions of U.S. Food and Drug Administration LabelingJACC, 2018
- 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in AdultsJACC, 2018
- 2015 ACC Health Policy Statement on Cardiovascular Team-Based Care and the Role of Advanced Practice ProvidersJACC, 2015
- The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studiesThe Lancet, 2007
- Clinical InertiaAnnals of Internal Medicine, 2001